Savara (NASDAQ:SVRA) Earns Market Outperform Rating from JMP Securities

JMP Securities reissued their market outperform rating on shares of Savara (NASDAQ:SVRA) in a research note published on Monday, Benzinga reports. They currently have a $8.00 price target on the stock.

Separately, Piper Sandler boosted their price target on shares of Savara from $7.00 to $16.00 and gave the stock an overweight rating in a report on Monday, March 4th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, Savara presently has a consensus rating of Buy and a consensus target price of $8.20.

Savara Trading Down 9.7 %

SVRA stock opened at $4.58 on Monday. Savara has a 52-week low of $1.87 and a 52-week high of $5.70. The company has a quick ratio of 15.66, a current ratio of 15.66 and a debt-to-equity ratio of 0.19. The firm has a market cap of $632.85 million, a P/E ratio of -15.36 and a beta of 0.73. The company’s 50-day simple moving average is $4.89 and its 200-day simple moving average is $4.52.

Savara (NASDAQ:SVRA) last issued its quarterly earnings results on Thursday, March 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.02. As a group, equities analysts forecast that Savara will post -0.38 EPS for the current fiscal year.

Institutional Investors Weigh In On Savara

Several hedge funds and other institutional investors have recently bought and sold shares of the company. AJOVista LLC purchased a new stake in shares of Savara in the 4th quarter valued at approximately $40,000. Principal Financial Group Inc. acquired a new position in Savara in the third quarter valued at approximately $48,000. Kestra Private Wealth Services LLC purchased a new position in Savara in the third quarter worth approximately $64,000. China Universal Asset Management Co. Ltd. acquired a new stake in Savara during the fourth quarter worth $74,000. Finally, Tower Research Capital LLC TRC raised its position in Savara by 665.6% in the fourth quarter. Tower Research Capital LLC TRC now owns 19,507 shares of the company’s stock valued at $92,000 after purchasing an additional 16,959 shares during the period. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.